Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta …,

(Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering …, (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering …, Read More